[Skip to Content]
[Skip to Content Landing]
July 1983

Immunosuppression With CyclosporineA New Approach to Improve Patency of Venous Allografts

Author Affiliations

From the Section of Surgical Research, Department of Surgery, Mount Carmel Mercy Hospital, Detroit.

Arch Surg. 1983;118(7):829-833. doi:10.1001/archsurg.1983.01390070039008

• In cases in which an autogenous vein is not available, the venous allograft still represents an interesting alternative; however, early occlusion of the allograft is the rule. Forty-five mongrel dogs received jugular allografts transplanted into the carotid artery. Group 1 (n=6) received no immunosuppression; group 2 (n=5) received systemic azathioprine (2.5 mg/kg/day). In group 3 (n = 10) the grafts were pretreated with cyclosporine at 4°C, and in group 4 (n = 9) the grafts were cryopreserved in a solution of 15% dimethyl sulfoxide and cyclosporine (50 mg/L) at—196 °C prior to implantation. Groups 3 and 4 received azathioprine as in group 2. Group 5 received cyclosporine systemically (15 to 20 mg/kg/day). Patency rates at one month (groups 1 and 2, 0%; group 3, 57.1%; groups 4 and 5,100%) indicate that cyclosporine improves venous allograft survival both when used systemically and as a graft pretreatment modality.

(Arch Surg 1983;118:829-833)